These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 17380085)

  • 21. Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD.
    Eisenstein BI; Oleson FB; Baltz RH
    Clin Infect Dis; 2010 Jan; 50 Suppl 1():S10-5. PubMed ID: 20067387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.
    Carpenter CF; Chambers HF
    Clin Infect Dis; 2004 Apr; 38(7):994-1000. PubMed ID: 15034832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Role of daptomycin in the empirical and directed therapy of infections caused by Gram-positive bacteria in the critically ill patient].
    Garnacho-Montero J; Amaya-Villar R; Gómez-Grande ML; Jerez V; Lorente-Ramos L; Loza A; Martínez A; Pozo JC; Sierra R; Pomares J; de la Torre MV; Ortiz C
    Rev Esp Quimioter; 2011 Mar; 24(1):13-24. PubMed ID: 21412665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003-2009).
    Sader HS; Farrell DJ; Jones RN
    J Chemother; 2011 Aug; 23(4):200-6. PubMed ID: 21803696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia.
    Hair PI; Keam SJ
    Drugs; 2007; 67(10):1483-512. PubMed ID: 17600394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on daptomycin: the first approved lipopeptide antibiotic.
    Lee SY; Fan HW; Kuti JL; Nicolau DP
    Expert Opin Pharmacother; 2006 Jul; 7(10):1381-97. PubMed ID: 16805723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daptomycin: Physicochemical, Analytical, and Pharmacological Properties.
    Tótoli EG; Garg S; Salgado HR
    Ther Drug Monit; 2015 Dec; 37(6):699-710. PubMed ID: 26020161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide.
    Sader HS; Streit JM; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2004 Nov; 50(3):201-4. PubMed ID: 15541606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Effectiveness, Safety Profile, and Pharmacokinetics of Daptomycin in Pediatric Patients: A Systematic Review.
    Karageorgos SA; Miligkos M; Dakoutrou M; Tsioutis C
    J Pediatric Infect Dis Soc; 2016 Dec; 5(4):446-457. PubMed ID: 27557822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
    Loza E; Morosini MI; Pascual A; Tubau F; Alcalá J; Liñares J; Hernández-Bello JR; Baquero F; Perea E; Martín R; Jones RN; Cantón R;
    Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New drugs; daptomycin].
    van Bronswijk H; Dubois EA; van Dissel JT; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Dec; 151(50):2777-8. PubMed ID: 18232197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Daptomycin in bone and joint infections: a review of the literature.
    Rice DA; Mendez-Vigo L
    Arch Orthop Trauma Surg; 2009 Nov; 129(11):1495-504. PubMed ID: 18989686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daptomycin.
    Tedesco KL; Rybak MJ
    Pharmacotherapy; 2004 Jan; 24(1):41-57. PubMed ID: 14740787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance.
    Lee SY; Kuti JL; Nicolau DP
    Surg Infect (Larchmt); 2005; 6(3):283-95. PubMed ID: 16201938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era.
    Ziglam H
    Expert Opin Pharmacother; 2007 Oct; 8(14):2279-92. PubMed ID: 17927483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of drug resistance: daptomycin resistance.
    Tran TT; Munita JM; Arias CA
    Ann N Y Acad Sci; 2015 Sep; 1354():32-53. PubMed ID: 26495887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current use of daptomycin in cardiac surgery and postoperative intensive care.
    Kanzler I; Weis F; Beiras-Fernandez A
    Expert Rev Anti Infect Ther; 2013 Mar; 11(3):309-20. PubMed ID: 23458770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Daptomycin: a cyclic lipopeptide antimicrobial agent.
    Jeu L; Fung HB
    Clin Ther; 2004 Nov; 26(11):1728-57. PubMed ID: 15639687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms.
    Streit JM; Jones RN; Sader HS
    J Antimicrob Chemother; 2004 Apr; 53(4):669-74. PubMed ID: 14985278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin.
    Vikram HR; Havill NL; Koeth LM; Boyce JM
    J Clin Microbiol; 2005 Oct; 43(10):5384-7. PubMed ID: 16208025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.